Search Medical Condition
Please enter condition
Please choose location

Eugene, Oregon Clinical Trials

A listing of Eugene, Oregon clinical trials actively recruiting patient volunteers.

RESULTS

Found (73) clinical trials

AdaptResponse Clinical Trial

The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

Phase

0.0 miles

Learn More »

A Study of MF101 in Postmenopausal Women

Menopausal women often experience debilitating menopausal vasomotor symptoms and associated insomnia. Until recently, vasomotor symptoms were often treated with estrogens, which are very effective; however, randomized clinical trials have shown that postmenopausal combination hormone therapy increases the risks for stroke, cardiovascular events, and breast cancer. New, more effective, and safer ...

Phase

0.0 miles

Learn More »

Randomized Placebo-controlled Multi-dose Study Comparing Budesonide/Formoterol to Symbicort in Asthmatic Patients

This is a pivotal trial that will examine therapeutic equivalence of a new generic fixed-dose combination product containing Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult patients with chronic but stable asthma as defined in National Asthma Education and ...

Phase

0.0 miles

Learn More »

Novel Combinations of CC-122 CC-223 CC-292 and Rituximab in Diffuse Large B-cell Lymphoma

Study CC-122-DLBCL-001 is a Phase 1b dose escalation and expansion clinical study of CC 122, CC-223 and CC-292 administered orally as doublets with or without rituximab, in subjects with relapsed/refractory DLBCL who have failed standard therapy.

Phase

0.81 miles

Learn More »

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma. In the combination portion of the study, the safety and tolerability of DCDS0780A in combination with rituximab or obinutuzumab will be assessed.

Phase

0.81 miles

Learn More »

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of Ineligibility For or Refusal of a Taxane Regimen

This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide alone in participants with mCRPC after failure of an androgen synthesis inhibitor (e.g., abiraterone) and failure of, ineligibility for, or refusal of a ...

Phase

0.81 miles

Learn More »

The purpose of this study is to assess the efficacy of INCB050465 in terms of objective response rate (ORR) in subjects with mantle cell lymphoma (MCL) that is relapsed or refractory after at least 1 but no more than 3 prior systemic treatment regimens.

Phase

0.81 miles

Learn More »

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will ...

Phase

1.14 miles

Learn More »

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.

Phase N/A

1.14 miles

Learn More »

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular Marginal Zone or Mantle Cell Lymphoma.

MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) who received ≥1 prior therapy and had stage I-IV, measurable disease. ~500 patients are planned for enrollment in 12 cycles of R2 ...

Phase

1.14 miles

Learn More »